KIDNEYCODE is a sponsored, no-charge genetic testing program to facilitate a personalized, precision medicine-based approach to CKD diagnosis, and contribute to the global understanding of genetic causes of CKD.
Publication: Alport Syndrome Classification and Management
A review of Alport syndrome epidemiology and the role of inflammation and Nrf2 in chronic kidney disease in patients with Alport syndrome.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020
Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.
Disclaimer
Omaveloxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease: Presentation at ERA-EDTA 2020
KIDNEYCODE is a sponsored, no-charge genetic testing program to facilitate a personalized, precision medicine-based approach to CKD diagnosis, and contribute to the global understanding of genetic causes of CKD.
Keap1/Nrf2 Pathway Regulates GFR by Increasing the Glomerular Effective Filtration Area Without Affecting the Afferent/Efferent Arteriole Ratio: Presentation at ERA-EDTA 2020
Pharmacologic and genetic investigation of the mechanisms of GFR regulation by Nrf2 using in vivo multiphoton microscope (MPM) imaging techniques.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: TSUBAKI, a Study of Bardoxolone Methyl in Patients with Diabetic CKD
TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Data Presentation: Topline Results from Year One of the CARDINAL Study of Bardoxolone Methyl in Alport Syndrome
The Phase 3 portion of CARDINAL is an international, multi-center, double-blind, placebo-controlled, randomized trial that enrolled 157 patients with chronic kidney disease caused by Alport syndrome. The primary endpoint for the study was the change in estimated glomerular filtration rate (eGFR) after 48 weeks of treatment. The key secondary endpoint for the study was the change in the off-treatment eGFR after 48 weeks of treatment and four weeks of drug withdrawal.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: Bardoxolone Methyl Analog Attenuates Proteinuria-Induced Tubular Damage by Modulating Mitochondrial Function
The effects of dihydro‐CDDO‐trifluoroethyl amide (dh404), a rodent‐tolerable bardoxolone methyl analog, on the tubulointerstitium, were tested in an Institute of Cancer Research‐derived glomerulonephritis (ICGN) mouse model of kidney disease. The effect of dh404 on mitochondrial function, was assessed using human proximal tubular cells in vitro.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: Effect of Bardoxolone Methyl on the Urine Albumin-To-Creatinine Ratio in Patients With Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Post-hoc analyses to characterize the relationship between the urine albumin-to-creatinine ratio and estimated glomerular filtration rate in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): The PHOENIX Study: Presentation at ASN KidneyWeek 2018
PHOENIX was a Phase 2, open-label, multi-center, US-only trial of bardoxolone methyl in four separate cohorts of patients with autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic chronic kidney disease, or focal segmental glomerulosclerosis. The trial enrolled 31 patients with autosomal dominant polycystic kidney disease and the primary endpoint was change in estimated glomerular filtration rate at Week 12.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with IgA Nephropathy: The PHOENIX Study: Presentation at ASN Kidney Week 2018
PHOENIX was a Phase 2, open-label, multi-center, US-only trial of bardoxolone methyl in four separate cohorts of patients with autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic chronic kidney disease, or focal segmental glomerulosclerosis. The trial enrolled 26 patients with IgA nephropathy and the primary endpoint was change in estimated glomerular filtration rate at Week 12.
Disclaimer
Bardoxolone is an investigational drugs. Safety and efficacy have not been established by any regulatory agency.
Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Type 1 Diabetes (T1D CKD): The PHOENIX Study: Presentation at ASN KidneyWeek 2018
PHOENIX was a Phase 2, open-label, multi-center, US-only trial of bardoxolone methyl in four separate cohorts of patients with autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic chronic kidney disease, or focal segmental glomerulosclerosis. The trial enrolled 28 patients with type 1 diabetic chronic kidney disease and the primary endpoint was change in estimated glomerular filtration rate at Week 12.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: Effects of Bardoxolone Methyl on Body Weight, Waist Circumference and Glycemic Control in Obese Patients with T2DM and Stage 4 Chronic Kidney Disease
Post-hoc analyses to characterize changes in body weight in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Data Presentation: Reata Announces Improvements in Kidney Function with Bardoxolone Methyl Maintained for Two Years in PAH Patients from LARIAT Trial
Reata announced results from the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension patients treated with bardoxolone methyl experienced kidney function improvements that were durable for two years and not associated with adverse outcomes.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
Post-hoc analyses to characterize changes in kidney function in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.
Publication: Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney
A preclinical investigation on the role of megalin, a protein involved in the tubular reabsorption of albumin and lipid-bound proteins, in changes in albuminuria in animals treated with bardoxolone methyl.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.